2020 Sip Club . . . 20 plus start-up projects gathered in Boao to seek to collide with head investment institutions.

On August 14, 2020, the Xipu Health Industry Capital Summit was held successfully.
in China's medical industry to upgrade the background of the times and the global epidemic normalization of the special moment, a considerable number of pharmaceutical research and development enterprises in the technical appearance of the "black horse" nature but because of the financial problems and unsustainable.
venture is designed to provide opportunities for biomedical research and development enterprises eager to seek the help of the capital market to communicate, exchange and cooperation with China's head investment institutions.
in order to seek cooperation, the founders of more than 20 pharmaceutical and health enterprises and IDG, Gautejia, Power Capital and more than 30 domestic top-level market investment representatives attended the meeting.
they are from the perspective of investors and entrepreneurs, each express their views, the meeting is wonderful.
this meeting invited to Guangzhou Xin Investment Consulting Management Co., Ltd. General Manager Peng Guoying as the chair of the meeting, a total of medical health investment and financing.
meeting opening 01 Huang Qing: the epidemic in the medical industry investment and financing stability, long-term investment logic remains unchanged the meeting to Gaotejia Investment CEO, Gaotejia Hongrui Investment Chairman Ms. Huang Qing brought "health industry under the protection of the value of re-judgment and investment strategy" as the theme of the keynote speech.
Gao Tejia is a representative of China's first-tier market investment institutions focusing on the field of biomedicine, Ms. Huang Qing made a comprehensive analysis of the current situation of investment and financing of biopharmaceuticals, entrepreneurial innovation opportunities and new investment strategies.
Huang Qing reviewed the stable performance of investment and financing in the medical industry-level market during the outbreak, and pointed out that biopharmaceuticals are the most popular investment and financing areas in the industry.
she highlighted market demand, policy benefits, the development of innovative drugs, and AI's revolutionary drive for the industry, which is preparing huge investment opportunities.
However, she also admitted that although most enterprises have high growth capacity, the overall valuation of pharmaceutical and health enterprises is still high, so we should firmly grasp the long-term investment logic, investment in the real solution to the industry pain point of innovative technology and service model companies.
Ms. Huang Qing's speech scene 028 high-quality innovation projects round-the-line roadshow, to the many investment institutions as the main play, the General Assembly organized 8 high development potential of new drugs, equipment quality projects theme roadshow.
roadshow companies these projects are located in innovative drug research and development, medical devices, AI intelligence and other track directions.
it is worth noting that these 8 projects are highly innovative, and seven of their founders are experts in research and development of hai-returned medicine, which fully reflects the trend of technological upgrading in China's pharmaceutical and health industry.
these companies are presenting themselves while also bringing the pharmaceutical industry's most advanced technology demonstrations to investors, including research and development of innovative anti-tumor drugs, the application of artificial intelligence in medical imaging, and innovative brain-computer interface products.
many of the first-tier market investors here have expressed strong interest in these projects, I believe there will be investment deals after the meeting.
8 enterprise roadshow scene 03 pharmaceutical investors looking for what? The last session of the 3 senior investment representatives to discuss the answers was the theme discussion entitled "What are pharmaceutical investors looking for in industrial upgrading".
theme discussion was chaired by Peng Guo, General Manager of Sean Investment, and invited Fan Dalong, Executive Partner of Gaotejia Investment, Zhang Jianbin, Partner of IDG Capital Medical Fund, and Zhou Yujian, Managing Partner of Power Capital, as panelists. the
theme discussion focuses on the new investment opportunities in the pharmaceutical industry in the industrial upgrading, the risks brought about by the major changes in the pharmaceutical industry to investment, the key factors for the success of pharmaceutical start-up projects, and the potential impact of the major changes in the pharmaceutical industry on fund raising.
guests express their views at the same time, entrepreneurs in the process of growth planning and development also has a strong enlightenment significance.
with the venture capital forum in the startup executives and investors in the docking, communication and exchange of the end, the 2020 Sip Capital Summit will be successfully concluded! Link industry and capital, we have been working hard.
year, we'll see you again!